Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker ACTU
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Oct 30, 2026 | SCHEDULE 13G | ACTU Actuate Therapeutics, Inc. | O'Neil Brendan | 4.23M | 7.7% | SCHEDULE 13G ↗ |
| Oct 30, 2026 | SCHEDULE 13G | ACTU Actuate Therapeutics, Inc. | Hexstone Capital LLC | 4.23M | 7.7% | SCHEDULE 13G ↗ |
| Apr 22, 2026 | SCHEDULE 13G/A (amended) | ACTU Actuate Therapeutics, Inc. | Voss Value-Oriented Special Situations Fund, LP | 50,000 | 0.2% | SCHEDULE 13G/A ↗ |
| Apr 22, 2026 | SCHEDULE 13G/A (amended) | ACTU Actuate Therapeutics, Inc. | Voss Value Master Fund, LP | 300,000 | 1.3% | SCHEDULE 13G/A ↗ |
| Apr 22, 2026 | SCHEDULE 13G/A (amended) | ACTU Actuate Therapeutics, Inc. | Voss Advisors GP, LLC | 350,000 | 1.5% | SCHEDULE 13G/A ↗ |
| Apr 22, 2026 | SCHEDULE 13G/A (amended) | ACTU Actuate Therapeutics, Inc. | Travis W. Cocke | 1.81M | 7.7% | SCHEDULE 13G/A ↗ |
| Apr 22, 2026 | SCHEDULE 13G/A (amended) | ACTU Actuate Therapeutics, Inc. | Voss Capital, LP | 1.81M | 7.7% | SCHEDULE 13G/A ↗ |
| Dec 17, 2025 | SCHEDULE 13G | ACTU Actuate Therapeutics, Inc. | Voss Value-Oriented Special Situations Fund, LP | 50,000 | 0.2% | SCHEDULE 13G ↗ |
| Dec 17, 2025 | SCHEDULE 13G | ACTU Actuate Therapeutics, Inc. | Voss Value Master Fund, LP | 200,000 | 0.9% | SCHEDULE 13G ↗ |
| Dec 17, 2025 | SCHEDULE 13G | ACTU Actuate Therapeutics, Inc. | Voss Advisors GP, LLC | 250,000 | 1.1% | SCHEDULE 13G ↗ |
| Dec 17, 2025 | SCHEDULE 13G | ACTU Actuate Therapeutics, Inc. | Travis W. Cocke | 1.23M | 5.3% | SCHEDULE 13G ↗ |
| Dec 17, 2025 | SCHEDULE 13G | ACTU Actuate Therapeutics, Inc. | Voss Capital, LP | 1.23M | 5.3% | SCHEDULE 13G ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Aaron G.L. Fletcher | 10.27M | 49.8% | SCHEDULE 13D/A ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Leslie W. Kreis | 8.73M | 42.6% | SCHEDULE 13D/A ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Advisors GP, LLC | 10.19M | 49.5% | SCHEDULE 13D/A ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Cavu Advisors, LLC | 8.66M | 42.2% | SCHEDULE 13D/A ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Capital Management, LP | 10.19M | 49.5% | SCHEDULE 13D/A ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Cavu Management, LP | 8.66M | 42.2% | SCHEDULE 13D/A ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Equity Cof, LP | 1.53M | 7.4% | SCHEDULE 13D/A ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Equity Partners III, LP | 5.96M | 29.2% | SCHEDULE 13D/A ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Equity Partners II, LP | 1.75M | 8.5% | SCHEDULE 13D/A ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Equity Partners, LP | 950,136 | 4.6% | SCHEDULE 13D/A ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios 2024 Co-Invest, LP | 267,856 | 1.3% | SCHEDULE 13D/A ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Clinical Opportunity Fund, LP | 1.26M | 6.2% | SCHEDULE 13D/A ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Actuate Co-Invest III, LP | 573,394 | 2.8% | SCHEDULE 13D/A ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Actuate Co-Invest II, LP | 2.09M | 10.2% | SCHEDULE 13D/A ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Actuate Co-Invest I, LP | 300,749 | 1.5% | SCHEDULE 13D/A ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | BP Directors, LP | 116,801 | 0.6% | SCHEDULE 13D/A ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Fund III NT, LP | 404,814 | 2.0% | SCHEDULE 13D/A ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Fund III QP, LP | 2.51M | 12.3% | SCHEDULE 13D/A ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Fund III, LP | 383,791 | 1.9% | SCHEDULE 13D/A ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Fund II NT, LP | 134,776 | 0.7% | SCHEDULE 13D/A ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Fund II QP, LP | 1.01M | 4.9% | SCHEDULE 13D/A ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Fund II, LP | 308,211 | 1.5% | SCHEDULE 13D/A ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Fund I QP, LP | 307,538 | 1.5% | SCHEDULE 13D/A ↗ |
| Jun 30, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Fund I, LP | 525,797 | 2.6% | SCHEDULE 13D/A ↗ |
| May 27, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Aaron G.L. Fletcher | 10.11M | 51.3% | SCHEDULE 13D/A ↗ |
| May 27, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Leslie W. Kreis | 8.73M | 44.4% | SCHEDULE 13D/A ↗ |
| May 27, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Advisors GP, LLC | 10.05M | 52.4% | SCHEDULE 13D/A ↗ |
| May 27, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Cavu Advisors, LLC | 8.66M | 44.0% | SCHEDULE 13D/A ↗ |
| May 27, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Capital Management, LP | 10.05M | 51.0% | SCHEDULE 13D/A ↗ |
| May 27, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Cavu Management, LP | 8.66M | 44.0% | SCHEDULE 13D/A ↗ |
| May 27, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Equity Cof, LP | 1.38M | 7.1% | SCHEDULE 13D/A ↗ |
| May 27, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Equity Partners III, LP | 5.96M | 30.4% | SCHEDULE 13D/A ↗ |
| May 27, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Equity Partners II, LP | 1.75M | 8.9% | SCHEDULE 13D/A ↗ |
| May 27, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Equity Partners, LP | 950,136 | 4.8% | SCHEDULE 13D/A ↗ |
| May 27, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios 2024 Co-Invest, LP | 125,000 | 0.6% | SCHEDULE 13D/A ↗ |
| May 27, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Clinical Opportunity Fund, LP | 1.26M | 6.4% | SCHEDULE 13D/A ↗ |
| May 27, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Actuate Co-Invest III, LP | 573,394 | 2.9% | SCHEDULE 13D/A ↗ |
| May 27, 2025 | SCHEDULE 13D/A (amended) | ACTU Actuate Therapeutics, Inc. | Bios Actuate Co-Invest II, LP | 2.09M | 10.7% | SCHEDULE 13D/A ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:42 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances